Researchers Develop Procedure for Early Oral Cancer Diagnosis
the Cancer Therapy Advisor take:
In 2012, approximately 300,000 patients were diagnosed with oral cancer worldwide. Since most patients with oral cancer are diagnosed at later stages of the disease, their treatment options are restricted to tumor biopsies or fine needle aspirations.
Pain, hoarse voice, difficulty swallowing, and swelling are symptoms indicative of oral cancer—or the common cold. To prevent misdiagnosing patients, Nham Tran, PhD, and Samantha Khoury, PhD candidate, developed a blood test for oral cancer detection.
Since no routine screening tests for oral cancer currently exist, the blood test, called miLIFE, could be implemented in the healthcare system since it is painless and easily administered by healthcare providers. Dr. Khoury said that the blood-based diagnostic test looks at microRNA, which are tiny molecules circulating in the blood. MiLIFE detects five specific microRNA levels and compares them to healthy microRNAs.
If the specific microRNAs are overexpressed, then the patient will be placed in a high-risk category for further examination. Benefits of miLIFE, according to Dr. Khoury, are a quick turnaround time of 48 hours and the fact that the diagnostic test does not require a specialist for administration.
General practitioners can check for microRNA biomarkers in the same blood sample for routine checks for vitamin D and cholesterol.
A quick and simple procedure would allow providers to screen for early signs of oral cancer.
Currently, there are no routine screening tests for oral cancer. But a simple blood test could change that, helping to stem the rise globally of oral cancers such as cancer of the throat, voice box, mouth and tongue.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia